我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

两种降尿酸药物治疗慢性心力衰竭伴高尿酸血症患者效果的比较

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2010年第5期
页码:
724-726
栏目:
临床研究
出版日期:
2010-06-22

文章信息/Info

Title:
Effects of urate-lowering drugs on chronic heart failure patients with hyperuricemia
作者:
朱俊国张林林李勋
苏州大学附属第一医院心内科,江苏 苏州 215006
Author(s):
ZHU Jun-guo ZHANG Lin-lin LI Xun
Department of Cardiology, First Affiliated Hospital, Suzou University, Suzou 215006, Jiangsu, China
关键词:
别嘌呤醇苯溴马隆心力衰竭慢性高尿酸血症
Keywords:
allopurinol benzbromarone chronic heart failure: hyperuricemia
分类号:
R541.6
DOI:
-
文献标识码:
A
摘要:
目的:比较两种降尿酸药物(别嘌呤醇和苯溴马隆)治疗慢性心力衰竭(CHF)伴高尿酸血症患者改善心功能的效果。方法: 选择伴高尿酸血症的CHF患者60例,随机分为3组,每组20例,接受常规治疗的为常规治疗组,在常规治疗基础上加服别嘌呤醇的为别嘌呤醇组,加服苯溴马隆者的为苯溴马隆组。治疗6个月后,对比各组血尿酸、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)治疗前后的变化。结果: 别嘌呤醇组和苯溴马隆组降低尿酸的效果相当;和常规治疗组相比别嘌呤醇组对心功能的改善更显著(P<0.05),而苯溴马隆组与常规治疗组的差异无统计学意义。结论: 抑制黄嘌呤氧化酶的别嘌呤醇对改善CHF患者心功能的作用优于单纯排尿酸的苯溴马隆。
Abstract:
AIM: To explore the effects of urate-lowering drugs (allopurinol and benzbromarone) on the heart function of chronic heart failure (CHF) patients complicated with hyperuricemia. METHODS: Sixty chronic heart failure patients complicated with hyperuricemia were selected and randomly divided into three groups. The control group was treated with conventional therapy, allopurinol group was treated with conventional therapy plus allopurinol and benzbromarone group was treated with conventional therapy plus benzbromarone. The changes of serum uric acid, left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDD) and left ventricular end-systolic volume (LVESD) before and after treatment were compared 6 months after treatment. RESULTS: Both allopurinol and benzbromarone were effective in lowering uric acid. Compared with that in control group, significantly improved heart function of CHF patients was observed in allopurinol group (P<0.05), whereas no significant difference was found between control group and benzbromarone group. CONCLUSION: Allopurinol is superior in improving cardiac function of CHF patients by inhibition of xanthine oxidase compared with benzbromarone by elimination of uric acid.

参考文献/References

[1]Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging[J]. Circulation, 2003, 107(15):1991-1997.

[2]Doehner W, von Haehling S, Anker SD. Uric acid in CHF: marker or playerin a metabolic disease[J]. Int J Cardiol, 2007, 115(2):156-158.

[3] Struthers AD, Donnan PT, Lindsay P, et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retros-pective cohort study[J]. Heart, 2002, 87(3):229-234.

[4]Mellin V, Isabelle M, Oudot A, et al. Transient reduction in Myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in esta-blished chronic heart failure[J]. Eur Heart J, 2005, 26(15):1544-1550.

[5] Palmer C, Vannucci RC, Towfighi J. Reduction of perinatal hypoxoc-ischemic brain damage with allopurinol[J]. Pediatr Res, 1990, 27(4):332-336.

[6] Hoey BM, Buller J, Halliwell B. On the specificity of allopurinol and oxypurinol as inhibitors of xanthine oxidase: a pulse radiolysis det- ermination of rate constants for reaction of allopurinol and oxypu- rinol with hydroxyl radicals[J]. Free Radic Res Commun, 1998, 4(4):259-263.

[7]Farquharson CA, Butler R, Hill A, et al. Allopufinol improves endothelial dysfunction in chronic heart failure[J]. Circulation, 2002, 106(2):221-226.

[8] Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen sythesis and matrix metalloproteinase activity in cardiac fibrobla- sts[J]. Am J Physiol Cell Physiol, 2001, 280(1):C53-C60.

[9] Engberding N, Spiekermann S, Schaefer A, et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myo-cardial infarction. A new action for an old drug?[J]. Circulation, 2004, 110(15):2175-2179.

[10]Perez NG, Gao WD, Marban E. Novel myofilament Ca2+-sensitizing Property of xanthine oxidase inhibitors[J]. Circ Res, 1998, 83(4):423-430.

备注/Memo

备注/Memo:
收稿日期:2008-08-21.通讯作者:李勋,主任医师,主要从事心肌梗死研究Email:XunLi58@126.com 作者简介:朱俊国,硕士生Email:xhdyzjg@sina.com
更新日期/Last Update: 2010-06-22